Russell Scott

Professor

New Zealand

Research Interests

Explore related searches

Professors in New Zealand

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Russell Scott is affiliated with NZ Clinical Research in New Zealand. His research primarily focuses on cardiovascular disease, diabetes-related complications, and therapeutic interventions for metabolic disorders. Recent publications include studies on haptoglobin levels and their association with diabetic retinopathy, as well as investigations into the efficacy of RNA interference therapeutics for non-alcoholic steatohepatitis.

Articles (12)

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Marja-Riitta Taskinen

University of Helsinki

FINLAND

View details

James Best

Visiting Professor

Nanyang Technological University (NTU)

SINGAPORE

View details

Jeong-Hoon Lee

Professor

Seoul National University Hospital

SOUTH KOREA

View details

Jonathan Williman

University of Otago

NEW ZEALAND

View details

Andrzej Januszewski

University of Sydney

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Russell Scott

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study

Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy

A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.

Corrigendum to “Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy” [Diab. Res. Clin. Pract. 186 (2022) 109835] (Diabetes Research and Clinical Practice (2022) 186, (S0168822722006477), (10.1016/j.diabres.2022.109835))

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.

Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy.

Type 1 diabetes diagnosed before age 15 years in Canterbury, New Zealand: A 50 year record of increasing incidence.

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.

Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes.

The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study.

Collaborators (5)

Marja-Riitta Taskinen

James Best

Jeong-Hoon Lee

Jonathan Williman

Andrzej Januszewski

Make your next move.